Here's Why Eli Lilly Stock Dropped 12% Last Month
Shares of Eli Lilly (NYSE: LLY) fell 20% in July, according to data from S&P Global Market Intelligence. The pharmaceutical stock tumbled after one of the company's competitors announced promising clinical trial news on an obesity drug. Lilly has two obesity products that are powering sales right now, and it could lose market share ahead of schedule if any of its rivals push smoothly through development.
On July 17, (OTC: RHHBY) announced favorable clinical results for a once-daily pill for weight loss and type 2 diabetes. The Swiss pharmaceutical company's candidate achieved clinically significant weight loss with a month of treatment in a phase 1 trial. Phase I trial results are still far from commercialization, but the announcement is an unquestionably positive step. It also marks Roche's second pipeline candidate for these sorts of indications.
IMAGE SOURCE: GETTY IMAGES.
Source Fool.com
Roche Holding AG ADR Stock
Based on 3 Buy predictions and 4 Sell predictions the sentiment towards Roche Holding AG ADR is rather balanced.
On the other hand, the target price of 38 € is above the current price of 36.86 € for Roche Holding AG ADR, so the potential is actually 3.09%.
